1 week Ago By Defense World Staff
LPL Financial LLC lessened its stake in shares of Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 16.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
The firm owned 8,154 shares of the company’s stock after selling 1,639 shares during the quarter. LPL Financial LLC’s holdings in Omnicell were worth $363,000 at the end of the most recent reporting period. Other institutional investors have also modified their holdings of the company.
Smartleaf Asset Management LLC boosted its position in shares of Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after purchasing an additional 273 shares during the period.
Van ECK Associates Corp lifted its position in Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after acquiring an additional 315 shares during the last quarter.
First Horizon Advisors Inc. grew its holdings in Omnicell by 36.3% in the 4th quarter.
First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after buying an additional 355 shares during the last quarter. Redmond Asset Management LLC boosted its holdings in Omnicell by 0.
3% in the 4th quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock valued at $5,396,000 after purchasing an additional 371 shares during the period. Finally, Hillsdale Investment Management Inc.
increased its stake in Omnicell by 0.5% during the fourth quarter. Hillsdale Investment Management Inc.
now owns 92,897 shares of the company’s stock valued at $4,136,000 after acquiring an additional 420 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.
Omnicell Stock PerformanceShares of NASDAQ OMCL opened at $30.96 on Friday. The stock has a market capitalization of $1.
45 billion, a PE ratio of 114.67, a price-to-earnings-growth ratio of 7.53 and a beta of 0.
78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.
22 and a current ratio of 1.37. Omnicell, Inc.
has a 52 week low of $25.12 and a 52 week high of $55.75.
The stock has a 50 day moving average price of $34.32 and a 200 day moving average price of $40.85.
Omnicell (NASDAQ:OMCL – Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.
57 by ($0.12). Omnicell had a net margin of 1.
13% and a return on equity of 3.82%. Analysts predict that Omnicell, Inc.
will post 1.09 earnings per share for the current fiscal year. Analysts Set New Price TargetsA number of analysts recently weighed in on OMCL shares.
Wells Fargo & Company lowered their target price on shares of Omnicell from $40.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 17th.
JPMorgan Chase & Co. dropped their target price on Omnicell from $44.00 to $36.
00 and set a “neutral” rating for the company in a research report on Thursday, March 20th. Benchmark reiterated a “buy” rating and set a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th.
StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a report on Friday. Finally, Bank of America decreased their target price on Omnicell from $54.
00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock.
According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $50.67.
Get Our Latest Analysis on OmnicellOmnicell Profile (Free Report)Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.See AlsoFive stocks we like better than OmnicellWhat is a Dividend King? Markets Think Robinhood Earnings Could Send the Stock UpWhat is the Euro STOXX 50 Index?Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains?What is Insider Trading? What You Can Learn from Insider TradingAT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround.
